139 related articles for article (PubMed ID: 11240256)
41. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
42. Radiation sensitization with redox modulators: a promising approach.
Rosenberg A; Knox S
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):343-54. PubMed ID: 16414370
[TBL] [Abstract][Full Text] [Related]
43. Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study.
Vogt HG; Kolotas C; Martin T; Schneider LV; Goes-Schmieder R; Mitrou PS; Diergarten K; Kober B; Zamboglou N
Semin Oncol; 1996 Dec; 23(6 Suppl 16):120-3. PubMed ID: 9007138
[TBL] [Abstract][Full Text] [Related]
44. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
Vink SR; Schellens JH; Beijnen JH; Sindermann H; Engel J; Dubbelman R; Moppi G; Hillebrand MJ; Bartelink H; Verheij M
Radiother Oncol; 2006 Aug; 80(2):207-13. PubMed ID: 16914220
[TBL] [Abstract][Full Text] [Related]
45. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
46. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
Langer CJ; Duffy K; Horwitz EM; Litwin S; Rosvold E; Schol J; Keenan E; Nicolaou N; Friedman CD; Ridge JA
Cancer Invest; 2006 Mar; 24(2):164-73. PubMed ID: 16537186
[TBL] [Abstract][Full Text] [Related]
47. Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer.
Herscher LL; Hahn SM; Kroog G; Pass H; Temeck B; Goldspiel B; Cook J; Mitchell JB; Liebmann J
J Clin Oncol; 1998 Feb; 16(2):635-41. PubMed ID: 9469352
[TBL] [Abstract][Full Text] [Related]
48. Reducing hemoglobin oxygen affinity does not increase hydroxyl radicals after acute subdural hematoma in the rat.
Doppenberg EM; Rice MR; Alessandri B; Qian Y; Di X; Bullock R
J Neurotrauma; 1999 Feb; 16(2):123-33. PubMed ID: 10098957
[TBL] [Abstract][Full Text] [Related]
49. Phase I study of hyperfractionated accelerated radiotherapy and escalating doses of daily cisplatin for patients with locally advanced non-small-cell lung cancer.
Schild SE; Wong WW; Vora SA; Halyard MY; Wheeler RH
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):729-34. PubMed ID: 12377324
[TBL] [Abstract][Full Text] [Related]
50. Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.
Koukourakis MI; Giatromanolaki A; Schiza S; Kakolyris S; Georgoulias V
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):107-14. PubMed ID: 9989521
[TBL] [Abstract][Full Text] [Related]
51. Detection of efaproxiral (RSR13) and its metabolites in equine by liquid chromatography tandem mass spectrometry.
Yi R; Sandhu J; Zhao S; Lam G; Loganathan D; Morrissey B
J Mass Spectrom; 2014 Jan; 49(1):57-67. PubMed ID: 24446264
[TBL] [Abstract][Full Text] [Related]
52. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
53. Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a phase I study.
Rosenthal DI; Okani O; Corak J; Kavanaugh D; Kamen B; Vuitch FM; Gazdar AF; Greiner J; Frenkel EF; Carbone DP
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-96-S12-100. PubMed ID: 9331130
[TBL] [Abstract][Full Text] [Related]
54. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study.
Bradley KA; Pollack IF; Reid JM; Adamson PC; Ames MM; Vezina G; Blaney S; Ivy P; Zhou T; Krailo M; Reaman G; Mehta MP;
Neuro Oncol; 2008 Oct; 10(5):752-8. PubMed ID: 18715950
[TBL] [Abstract][Full Text] [Related]
55. Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer--results from a Phase I trial.
Hoffmann W; Belka C; Schmidberger H; Budach W; Bochtler H; Hess CF; Bamberg M
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):691-6. PubMed ID: 9240634
[TBL] [Abstract][Full Text] [Related]
56. Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002).
Nishimura Y; Nakagawa K; Takeda K; Tanaka M; Segawa Y; Tsujino K; Negoro S; Fuwa N; Hida T; Kawahara M; Katakami N; Hirokawa K; Yamamoto N; Fukuoka M; Ariyoshi Y
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):786-92. PubMed ID: 17512126
[TBL] [Abstract][Full Text] [Related]
57. Efaproxiral: a radiation enhancer used in brain metastases from breast cancer.
Charpentier MM
Ann Pharmacother; 2005 Dec; 39(12):2038-45. PubMed ID: 16249270
[TBL] [Abstract][Full Text] [Related]
58. Pharmacological correction of hypothermic P(50) shift does not alter outcome from focal cerebral ischemia in rats.
Wainwright MS; Sheng H; Sato Y; Mackensen GB; Steffen RP; Pearlstein RD; Warner DS
Am J Physiol Heart Circ Physiol; 2002 May; 282(5):H1863-70. PubMed ID: 11959653
[TBL] [Abstract][Full Text] [Related]
59. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
60. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
